首页> Cancer investigation> Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas.

Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas.

导出原文传递

翻译打印收藏纠错

作者： Edmonson JH ^[1] ; Marks RS ^[2] ; Buckner JC ; Mahoney MR

作者单位： Mayo Clinic, Rochester, MN 55905, USA. edmoj ^[1] harm.sunysb.edu ^[2]

关键词 Gastrointestinal Neoplasms Leiomyosarcoma Uterine Neoplasms 胃肠肿瘤平滑肌肉瘤子宫肿瘤

发布时间 2013-11-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览1

Cancer investigation

2002年20卷5/6期

605-612页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览1

点击下载本期目录封面

Cancer investigation

2002年20卷5/6期

605-612页

检索历史清除

Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas.

Cancer investigation

相似文献

Cancer investigation

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas.

Cancer investigation

相似文献

Cancer investigation

相关期刊

检索历史清除